Literature DB >> 21339844

Carrier-based intralymphatic cisplatin chemotherapy for the treatment of metastatic squamous cell carcinoma of the head & neck.

Shuang Cai1, Yumei Xie, Neal M Davies, Mark S Cohen, M Laird Forrest.   

Abstract

BACKGROUND: Since head and neck squamous cell carcinoma (HNSCC) preferentially metastasizes to the locoregional lymphatics, treatment of the tumor-draining cervical lymph nodes is paramount.
RESULTS: We developed a hyaluronan-cisplatin (HA-Pt) nanoconjugate with prolonged lymphatic retention and greatly improved tumor tissue deposition for the treatment of metastatic HNSCC. We also developed an orthotopic metastatic xenograft model of HNSCC to examine the efficacy of the nanoconjugate. HNSCC (1/week x 3 weeks) were completely cured for 57% of the female mice in the HA-Pt treatment group, which demonstrated greatly hindered HNSCC progression compared with the standard cisplatin therapy (p < 0.05).
CONCLUSION: With this insight, we will be able to optimize the carriers for better uptake, penetration and retention within cancer cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21339844      PMCID: PMC3039877          DOI: 10.4155/tde.10.38

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  25 in total

1.  The protective effect of erdosteine against ototoxicity induced by cisplatin in rats.

Authors:  M Tayyar Kalcioglu; Ahmet Kizilay; Mukaddes Gulec; Erkan Karatas; Mustafa Iraz; Omer Akyol; Mucahit Egri; Orhan Ozturan
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-03-02       Impact factor: 2.503

2.  Prevention of noise- and drug-induced hearing loss with D-methionine.

Authors:  Kathleen C M Campbell; Robert P Meech; James J Klemens; Michael T Gerberi; Sara S W Dyrstad; Deb L Larsen; Diana L Mitchell; Mohammed El-Azizi; Steven J Verhulst; Larry F Hughes
Journal:  Hear Res       Date:  2007-01-16       Impact factor: 3.208

3.  Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants.

Authors:  W J Clerici; K Hensley; D L DiMartino; D A Butterfield
Journal:  Hear Res       Date:  1996-09-01       Impact factor: 3.208

4.  The impact of nutritional status on the prognoses of patients with advanced head and neck cancer.

Authors:  P A van Leeuwen; D J Kuik; W M Klop; H P Sauerwein; G B Snow; J J Quak
Journal:  Cancer       Date:  1999-08-01       Impact factor: 6.860

5.  Intratumoral delivery of paclitaxel-loaded poly(lactic-co-glycolic acid) microspheres for Hep-2 laryngeal squamous cell carcinoma xenografts.

Authors:  Ming Xie; Liang Zhou; Tao Hu; Ming Yao
Journal:  Anticancer Drugs       Date:  2007-04       Impact factor: 2.248

6.  Pattern of occurrence of head and neck cancer presenting at Kenyatta National Hospital, Nairobi.

Authors:  J F Onyango; D O Awange; A Njiru; I M Macharia
Journal:  East Afr Med J       Date:  2006-05

7.  Pharmacokinetics and disposition of a localized lymphatic polymeric hyaluronan conjugate of cisplatin in rodents.

Authors:  Shuang Cai; Yumei Xie; Neal M Davies; Mark S Cohen; M Laird Forrest
Journal:  J Pharm Sci       Date:  2010-06       Impact factor: 3.534

8.  Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig.

Authors:  Andreas Ekborn; Annika Lindberg; Göran Laurell; Inger Wallin; Staffan Eksborg; Hans Ehrsson
Journal:  Cancer Chemother Pharmacol       Date:  2002-11-02       Impact factor: 3.333

9.  Impaired hydrolysis of cisplatin derivatives to aquated species prevents energy-dependent uptake in GLC4 cells resistant to cisplatin.

Authors:  Elene Pereira-Maia; Arlette Garnier-Suillerot
Journal:  J Biol Inorg Chem       Date:  2003-05-17       Impact factor: 3.358

10.  Cisplatin-albumin complex for treatment of cancer of the head and neck.

Authors:  G C Vreeburg; P M Stell; J D Holding; W E Lindup
Journal:  J Laryngol Otol       Date:  1992-09       Impact factor: 1.469

View more
  18 in total

1.  Effects of peritumoral nanoconjugated cisplatin on laryngeal cancer stem cells.

Authors:  Michael W Sim; Patrick T Grogan; Chitra Subramanian; Carol R Bradford; Thomas E Carey; M Laird Forrest; Mark E Prince; Mark S Cohen
Journal:  Laryngoscope       Date:  2015-12-21       Impact factor: 3.325

2.  Multi-arm polymeric nanocarrier as a nitric oxide delivery platform for chemotherapy of head and neck squamous cell carcinoma.

Authors:  Shaofeng Duan; Shuang Cai; Qiuhong Yang; M Laird Forrest
Journal:  Biomaterials       Date:  2012-01-26       Impact factor: 12.479

Review 3.  From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity.

Authors:  Natalie L Trevaskis; Lisa M Kaminskas; Christopher J H Porter
Journal:  Nat Rev Drug Discov       Date:  2015-10-16       Impact factor: 84.694

4.  Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines.

Authors:  Ti Zhang; Shuang Cai; Chad Groer; Wai Chee Forrest; Qiuhong Yang; Eva Mohr; Justin Douglas; Daniel Aires; Sandra M Axiak-Bechtel; Kimberly A Selting; Jeffrey A Swarz; Deborah J Tate; Jeffrey N Bryan; M Laird Forrest
Journal:  J Pharm Sci       Date:  2016-05-04       Impact factor: 3.534

5.  Phase I-II clinical trial of hyaluronan-cisplatin nanoconjugate in dogs with naturally occurring malignant tumors.

Authors:  Shuang Cai; Ti Zhang; W C Forrest; Qiuhong Yang; Chad Groer; Eva Mohr; Daniel J Aires; Sandra M Axiak-Bechtel; Brian K Flesner; Carolyn J Henry; Kimberly A Selting; Deborah Tate; Jeffrey A Swarz; Jeffrey N Bryan; M Laird Forrest
Journal:  Am J Vet Res       Date:  2016-09       Impact factor: 1.156

6.  Prevention of nodal metastases in breast cancer following the lymphatic migration of paclitaxel-loaded expansile nanoparticles.

Authors:  Rong Liu; Denis M Gilmore; Kimberly Ann V Zubris; Xiaoyin Xu; Paul J Catalano; Robert F Padera; Mark W Grinstaff; Yolonda L Colson
Journal:  Biomaterials       Date:  2012-12-08       Impact factor: 12.479

7.  Intratracheal Administration of Hyaluronan-Cisplatin Conjugate Nanoparticles Significantly Attenuates Lung Cancer Growth in Mice.

Authors:  Susumu Ishiguro; Shuang Cai; Deepthi Uppalapati; Katie Turner; Ti Zhang; Wai Chee Forrest; M Laird Forrest; Masaaki Tamura
Journal:  Pharm Res       Date:  2016-06-22       Impact factor: 4.200

8.  Cellular uptake and internalization of hyaluronan-based doxorubicin and cisplatin conjugates.

Authors:  Shuang Cai; Adel Ali B Alhowyan; Qiuhong Yang; W C Melanie Forrest; Yelizaveta Shnayder; M Laird Forrest
Journal:  J Drug Target       Date:  2014-06-03       Impact factor: 5.121

9.  In vivo efficacy of nano hyaluronan-conjugated cisplatin for treatment of murine melanoma.

Authors:  Qiuhong Yang; Daniel J Aires; Shuang Cai; Garth R Fraga; Da Zhang; Cicy Z Li; M Laird Forrest
Journal:  J Drugs Dermatol       Date:  2014-03       Impact factor: 2.114

10.  Intratumoral Cancer Chemotherapy with a Carrier-Based Immunogenic Cell-Death Eliciting Platinum (IV) Agent.

Authors:  Chad Groer; Ti Zhang; Ruolin Lu; Shuang Cai; Derek Mull; Aric Huang; Melanie Forrest; Cory Berkland; Daniel Aires; Marcus Laird Forrest
Journal:  Mol Pharm       Date:  2020-10-08       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.